Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic CoreValve Meets Targets In Extreme-Risk Group; Panel Will Not Be Needed, FDA Says

This article was originally published in The Gray Sheet

Executive Summary

The firm now expects to gain approval for the extreme-risk indication of its transcatheter aortic heart valve months earlier than earlier predicted following well-received pivotal trial data reported last week at the Transcatheter Cardiovascular Therapeutics meeting.

You may also be interested in...



Medtronic Touts New Products, Advantages Of TAVR In Post-CABG Patients

Medtronic launched new sizes of its repositionable transcatheter aortic valve replacement system. It also recently reported data for its first-generation CoreValve showing a benefit in high risk patients who had previously undergone coronary artery bypass surgery.

TAVR Performance Sustained In Long-Term Data

Five-year follow-up data on Edwards’ Sapien and two-year data on Medtronic’s CoreValve presented at the TCT conference in Washington, D.C., show sustained efficacy and safety for transcatheter aortic valves in patients too ill for surgery.

News Briefs: Medtronic’s CoreValve Approval; J&J Dx Unit Set For Sale; Google’s Glucometer Contact Lens

Medtronic gains FDA approval for its transcather CoreValve system months earlier than predicted. The Carlyle Group makes binding offer for J&J’s Ortho-Clinical Diagnostics business. Google is developing a wireless glucometer embedded within a contact lens. More news briefs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT032561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel